Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 293

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Photobiomodulation or low‐level laser therapy

Open access
Hamblin, Michael R. · 2016 · Journal of Biophotonics

Abstract

It is not often that the globally accepted name of a scientific field has changed between the time at which a journal commissions a special issue and the time at which the actual issue goes to press. Such has been the case here. Low-level laser (light) therapy (formerly abbreviated as LLLT) is approaching its 50th anniversary. LLLT was discovered in 1967 by Endre Mester at the Semmelweis Medical University in Hungary. Mester was trying to repeat an experiment first conducted by Paul McGuff in Boston USA, who had successfully used the newly discovered ruby laser to cure malignant tumors in rats 1. However, Mester's custom-made ruby laser possessed only a very small fraction of the power possessed by McGuff's laser. Despite not curing any tumors with his low-power laser beam, he did observe a heightened rate of hair growth and better wound healing in the rats in which he had surgically implanted tumors. This was the first indication that low-level laser light (rather than high power thermal lasers) could have its own beneficial applications in medicine 2, 3. Since those early days, it has been consistently found that one did not, in fact, need to use a coherent monochromatic laser to obtain these beneficial biological effects, but rather non-coherent light-emitting diodes (LEDs) with comparable parameters to low power lasers performed equally well. Considering that lasers were shown not to be necessary, the fact that "low-level" was considered a subjective term and nobody knew exactly what the term "low" actually meant, the fact that both inhibition as well as stimulation of biological processes could be therapeutically useful, the decision was eventually made to change the name to "photobiomodulation (therapy)" abbreviated PBM(T) depending on whether the process or a treatment is being discussed 4. Photobiomodulation has made, and is continuing to make, major progress in obtaining recognition from authorities in medical schools, scholarly journals, the popular press and media, medical practitioners, therapists and other bodies concerned with biomedical science. This progress was very necessary as only about ten years ago the general consensus was that LLLT was "snake oil" and only practised by charlatans. Several influential "systematic reviews" including the Cochrane Database Organization concluded that LLLT had found "no reliable evidence" for efficacy in diseases such as osteoarthritis, rheumatoid arthritis, etc. 5. Another problem involved the prevailing use of a wide variety of different kinds of light sources (medical devices) and treatment protocols including, illumination parameters (such as: wavelength, fluence, power density, pulse structure, etc.) and the fact that there was no agreement on the treatment schedule. Unfortunately, these variations in study designs led to an increase in the number of negative trials that were published and created some controversy, despite the overwhelming number of positive clinical results that were also obtained 6. This change in perception that has occurred in recent years can be attributed to several factors, but perhaps the most important among these considerations is the progress that has been made in understanding the mechanisms of action at a molecular, cellular and tissue-based level 7. The work of Tiina Karu in Russia was instrumental in putting the mechanism on a sound footing by identifying cytochrome c oxidase in the mitochondrial respiratory chain as a primary chromophore, and it introduced the concept of "retrograde mitochondrial signalling" to explain how a single relatively brief exposure to light could have effects on the organism that lasted for hours, days or even weeks 8. Several professional and learned societies are now wholly devoted to photobiomodulation: World Association of Laser Therapy (WALT); North American Association for Photobiomodulation Therapy (NAALT); or partly devoted: SPIE Photonics West; American Society of Lasers in Medicine and Surgery (ASLMS); and (soon) Optical Society of America (OSA). Many different diseases, conditions, and fields of medical treatment are now becoming amenable to the beneficial effects of PBM 9. Several of these innovative applications are discussed in papers included in this special issue of Journal of Biophotonics. It is abundantly clear from surveying the countries of origin of many of the papers included in this issue, that Brazil (11 out of 15 contributions) has a remarkable number of productive laboratories investigating PBM-related topics. Advances have been made in cell culture studies that have gone a great distance towards elucidating the mechanisms of action of PBM that previously was largely considered a "black box". This lack of mechanism was often quoted by detractors as a reason why PBM should not be taken seriously. There are several studies related to in vitro studies in cell culture in the present special issue. A contribution from the Rogers laboratory at the Harvard School of Public

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jbio.201670113

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

Metadata

Authors
Hamblin, M. R.
Venue
Journal of Biophotonics
Publisher
Wiley
Published
2016-12
Volume
9
Issue
11-12
Pages
1122-1124
ISSN
  • 1864-063X (ISSN-L)
  • 1864-0648
OpenAlex
W2566680017
Cited by
293
References
5
FWCI
6.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.